CD177 and B-cell chronic lymphocytic leukemia: As antibodies targeting a single cell surface receptor can have completely different functionalities and mechanisms of action depending on epitope, as seen for the various antibodies specific for CD20 commonly used for treatment of CLL (Beers et al., 2010), these findings illustrate an approach to discover antibodies with rare epitope specificity also on complex targets like intact cells.